Compare Gilead Sciences, Inc. (GILD) vs Nutrien Ltd (NTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Nutrien Ltd — how do they compare? Gilead Sciences, Inc. trades at $133.5 (market cap $163.51B), while Nutrien Ltd trades at $67 (market cap $32.46B). The key difference: Gilead Sciences, Inc. is far larger — about 5× Nutrien Ltd's market cap, and Nutrien Ltd pays the higher dividend (3.22%). Which is the better fit depends on your goals.
| GILD | NTR | |
|---|---|---|
Market Cap | $163.51B | $32.46B |
Sector | Health | Basic Materials |
52-Week High | $155.80 | $83.94 |
52-Week Low | $108.22 | $53.64 |
Enterprise Value | $178.05B | $45.62B |
Dividend Yield | 2.49% | 3.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Nutrien (NTR) trades at $67.04, down 2.33% on the day, with a bullish technical signal from moving averages but bearish oscillators. The company shows improving fundamentals with Q1 2026 EPS beating expectations and a net income margin of 8.58%. Recent news highlights strong fertilizer demand and cost-cutting efforts, though input cost pressures persist. Cash flow trends indicate consistent operational strength despite negative net cash flow in recent periods.
Outlook remains positive with analyst consensus pointing to a $77.67 price target and 63.64% buy ratings. Key opportunities include robust potash sales and healthy industry demand, while risks involve volatile input costs and margin compression from supply chain challenges. The stock presents a value proposition with a P/E of 13.92 trading below analyst targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →
